Publications by authors named "Takaharu Yo"
Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis.
Aya Takahashi Michihisa Moriguchi Yuya Seko Toshihide Shima Yasuhide Mitsumoto Yo Takaharu Naomi Yoshinami Hironori Mitsuyoshi Yoshito Itoh
Cancers (Basel)
March 2020
We investigated the association between early tumor shrinkage (ETS) and treatment outcome in patients with hepatocellular carcinoma treated with lenvatinib (LEN). A retrospective analysis was performed in 104 patients. ETS was defined as tumor shrinkage at the first evaluation in the sum of target lesions' longest diameters from baseline according to the Response Evaluation Criteria in Solid Tumors (RECIST).
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed 50 patients with hepatocellular carcinoma (HCC) treated with lenvatinib, focusing on factors affecting their response to the drug.
- A significant finding showed that the relative dose intensity after 8 weeks (8W-RDI) was the only factor linked to treatment response, with a cutoff of 75%.
- Patients who maintained an 8W-RDI of 75% or higher had better response rates and longer progression-free survival compared to those with lower RDI.